Pharsight

Nevakar Injectables patents expiration

1. Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11413259 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10420735 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10226436 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10159657 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10568850 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US11602508 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 06 October, 2022

Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic